Hepatocanalicular injury associated with vitamin A derivative etretinate. An idiosyncratic hypersensitivity reaction.
A patient with pustular psoriasis developed jaundice, peripheral blood eosinophilia, and biochemical evidence of hepatocanalicular dysfunction four weeks after the initiation of etretinate therapy. A liver biopsy specimen showed bile duct damage, a periportal inflammatory infiltrate composed of neutrophils, eosinophils and lymphocytes, canalicular cholestasis, and focal hepatocyte necrosis. Clinical exclusion of other possible etiologic factors coupled with near resolution of the biochemical abnormalities within six weeks after complete discontinuation of the drug indicates that etretinate may induce an idiosyncratic hypersensitivity reaction. This is the first report to document etretinate associated bile duct injury.
D000368:Aged; D001648:Bile Canaliculi / Q000187:drug effects* / Q000473:pathology; D001649:Bile Duct Diseases / Q000139:chemically induced / Q000473:pathology; D001653:Bile Ducts, Intrahepatic / Q000187:drug effects*; D002780:Cholestasis, Intrahepatic / Q000139:chemically induced; D004342:Drug Hypersensitivity / Q000473:pathology*; D005050:Etretinate / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D011565:Psoriasis / Q000188:drug therapy
D005050:Etretinate